Recruiting
Clarifying the Optimal Application of SLT Therapy Trial
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
ClinicalTrials.gov IDNCT04967989
PhasePHASE3
Enrollment790
SponsorUniversity of Pittsburgh
Age18 Years
SexALL
Conditions studied
Glaucoma and Ocular Hypertension
About this study
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Interventions
- Procedure: Low Energy SLT — SLT performed at low energy
- Procedure: Standard Energy SLT — SLT performed at standard energy
Primary outcomes
- 12-month survival (12 months)
- 48-month survival (48 months)
Eligibility information
Inclusion Criteria:
1. Age 18 or older and in good health
2. Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes):
1. High-risk ocular hypertension (OHT): IOP \> 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of \>0.2 between eyes)
2. Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° \<15 dB (see figure on next page)
3. Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points \<15 dB or mean deviation -12.0 dB or better with 1 central 5° points \<15 dB (see figure on next page).
3. Each eye with BCVA 20/200 (UK 6/60) or better
Exclusion Criteria:
1. Use of topical IOP-lowering medications for more than 6 cumulative months at any time in the past 5 years (this is a modification implemented during active enrollment)
2. Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgical procedure
3. Advanced POAG in either eye (worse than moderate POAG as defined above)
4. Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) in either eye
5. Mean IOP \> 35 mmHg at either the screening or baseline visit in either eye
6. Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye
7. Contraindications to SLT or any other study intervention
8. Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye
9. Any intraocular surgical procedure within the past 6 months in either eye
10. Inability to attend all scheduled study visits
11. Pregnant or planning to become pregnant in the next 4 years
Study locations
- Harvard Eye Associates, Laguna Hills, California 92653 United States
- Doheny Eye Center UCLA, Pasadena, California 91105 United States
- University of California, Davis, Sacramento, California 95817 United States
- University of California, San Francisco, San Francisco, California 94158 United States
- Mile High Eye Institute, Sheridan, Colorado 80110 United States
- Clear Vue Laser Eye Center, Lakeworth, Florida 33467 United States
- Northwestern Medical Group, Chicago, Illinois 60615 United States
- Chicago Arbor Eye Institute, Orland Park, Illinois 60467 United States
- Illinois Eye Center, Peoria, Illinois 61615 United States
- Wilmer Eye Institute Johns Hopkins, Baltimore, Maryland 21287 United States
Showing 10 of 29 reported sites. See the official listing for all locations.
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.